Blood Res.  2016 Dec;51(4):297-299. 10.5045/br.2016.51.4.297.

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab

• Jung CW
• Cho SH
• Park S
• Jang JH
• Ji JH

• KMID: 2364326
• DOI: http://doi.org/10.5045/br.2016.51.4.297

Abstract

No abstract available.

MeSH Terms

Purpura, Thrombocytopenic, Idiopathic*

Figure

• 

  Fig. 1 Platelet count after alemtuzumab treatment.Abbreviations: Pt1, patient 1; Pt2, patient 2.

• 

  Fig. 2 CD4+, CD8+, CD4+/CD25+ lymphocyte count after alemtuzumab treatment. (A) CD4+ lymphocyte, (B) CD8+ lymphocyte, (C) CD4+/CD25+ lymphocyte.Abbreviations: Pt1, patient 1; Pt2, patient 2.

Reference

1. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113:6511–6521. PMID: 19395674.

2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115:168–186. PMID: 19846889.

3. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90:72–77. PMID: 15642672.

4. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146:25–33. PMID: 17200219.

5. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377:393–402. PMID: 20739054.

6. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010; 116:4783–4785. PMID: 20841509.

7. Pham DC, Guthrie TH, Villas BH, Salazar E. Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab. Am J Hematol. 2008; 83:603.

8. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002; 100:1715–1720. PMID: 12176892.

9. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003; 101:1422–1429. PMID: 12393688.

10. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006; 120:247–259. PMID: 16797237.

11. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica. 2004; 89:1476–1483. PMID: 15590398.

12. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res. 2004; 28:495–507. PMID: 15068903.

13. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6:443–446. PMID: 10742152.

14. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110:2924–2930. PMID: 17548576.

15. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52:501–513. PMID: 15693003.